Responses
Late-breaking abstracts
Novel single-agent immunotherapies
862 Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth
Compose a Response to This Article
Other responses
No responses have been published for this article.
